Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 8/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394234 | 0.90 | RIPK1 (0.41) | MTNR1AMTNR1BRIPK1GAAKMT2A | |
| SCHEMBL20580042 | 0.86 | DDB1 (0.51) | RIPK1SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL20580043 | 0.86 | DDB1 (0.51) | RIPK1SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL22363308 | 0.84 | FPR2 (0.50) | KMT2AMEN1 | |
| SCHEMBL542468 | 0.84 | RIPK1 (0.39) | MTNR1AMTNR1BRIPK1GAAKMT2A | |
| SCHEMBL22363306 | 0.84 | EPHX2 (0.46) | MTNR1AMTNR1BRIPK1GAAKMT2A | |
| SCHEMBL6827497 | 0.84 | EPHX2 (0.46) | MTNR1AMTNR1BRIPK1GAAKMT2A | |
| SCHEMBL6827502 | 0.84 | EPHX2 (0.46) | MTNR1AMTNR1BRIPK1GAAKMT2A | |
| SCHEMBL6176791 | 0.81 | NAAA (0.48) | GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL8893179 | 0.80 | MAPT (0.48) | MTNR1AMTNR1BSMN1; SMN2PTGDR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415766-A1 | METHOD FOR MANUFACTURING BENZODIAZEPINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120010401-A1 | METHOD FOR MANUFACTURING 1,5-BENZODIAZEPINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010401-A1 | METHOD FOR MANUFACTURING 1,5-BENZODIAZEPINE DERIVATIVE | GABRA5, CYP3A5, GABRA1 | MTNR1A 610/4885MTNR1B 431/4885RIPK1 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.